Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C48400
http://purl.obolibrary.org/obo/NCIT_C48400
|
|---|---|
| Preferred Name | Iodine I 131 Omburtamab |
| Definitions |
A radioimmunoconjugate consisting of the iodine 131-radiolabeled murine IgG1 monoclonal antibody 8H9 directed against the surface immunomodulatory glycoprotein 4Ig-B7-H3 with potential radioimaging and radioimmunotherapeutic uses. Iodine I 131 monoclonal antibody 8H9 binds to 4Ig-B7-H3 (human B7-H3 with 4 Ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4Ig-B7-H3 inhibits T-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mdDCs). In vitro, it has been shown that monoclonal antibody-mediated masking of 4Ig-B7-H3 on neuroblastoma cells resulted in the enhancement of natural killer (NK)-mediated lysis of target cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A radioimmunoconjugate consisting of the iodine 131-radiolabeled murine IgG1 monoclonal antibody 8H9 directed against the surface immunomodulatory glycoprotein 4Ig-B7-H3 with potential radioimaging and radioimmunotherapeutic uses. Iodine I 131 monoclonal antibody 8H9 binds to 4Ig-B7-H3 (human B7-H3 with 4 Ig-like domains) and may be used to radioimage and/or destroy tumor cells that express tenascin. 4Ig-B7-H3 inhibits T-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mdDCs). In vitro, it has been shown that monoclonal antibody-mediated masking of 4Ig-B7-H3 on neuroblastoma cells resulted in the enhancement of natural killer (NK)-mediated lysis of target cells. |
|---|---|
| prefLabel | Iodine I 131 Omburtamab
|
| label | Iodine I 131 Omburtamab
|
| PDQ_Closed_Trial_Search_ID | 380753
|
| code | C48400
|
| Has_Target | |
| prefixIRI | NCIT:C48400
|
| in_subset |
See more
See less
|
| Display_Name | Iodine I 131 Omburtamab
|
| Preferred_Name | Iodine I 131 Omburtamab
|
| FDA_UNII_Code | B6PMV8U3C4
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Iodine I 131 Omburtamab
|
| NCI_Drug_Dictionary_ID | 380753
|
| Legacy Concept Name | Iodine_I_131_Monoclonal_Antibody_8H9
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 380753
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1541591
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |